Alzinova has presented new clinical results showing that healthy older people naturally have high levels of protective antibodies against toxic amyloid-β oligomers, while levels are reduced in Alzheimer's patients. The company's vaccine ALZ-101 raises these antibody levels in Alzheimer's patients to the same level as in healthy control subjects.
Alzinova presents promising antibody data
Notes
Cantargia publishes data for nadunolimab in lung cancer
Genmab reports sales of DARZALEX
AlzeCure receives additional subscription commitments of SEK 7 million
AstraZeneca updates on phase III study
Orexo maintains full-year forecast despite currency headwinds
BioGaia launches subsidiary for microbiome research
Isofol receives positive FDA feedback for arfolitixorin
NEWSLETTER
Upcoming events
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Recommended
Trump threatens 200 percent tariffs on pharmaceuticals
AbbVie acquires Capstan Therapeutics for up to $2,1 billion
GLP-1 drugs drive pharmaceutical boom to 2030
FDA introduces fast track for drugs of national importance
Monetization of future royalties increasingly popular
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Today's news roundup
